PD-1单克隆抗体联合血管内皮抑素在Lewis肺癌小鼠的抗肿瘤效应
Combinatorial anti-PD-1 and endostatin therapeutic efficacy in Lewis lung cancer mice

DOI: 10.6040/j.issn.1671-7554.0.2018.251

Keywords: 肺肿瘤,程序性死亡受体-1,肿瘤微环境,血管内皮抑素,
Programmed cell death-1,Lung cancer,Tumor microenvironment,Endostatin

Full-Text   Cite this paper   Add to My Lib

Abstract:

References

[1]	Peng Q, Li M, Wang Z, et al. Polarization of tumor-associated macrophage is associated with tumor vascular normalization by endostatin[J]. Thorac Cancer, 2013, 4(3): 295-305.
[2]	Folkman J. Tumor angiogenesis: therapeutic implications[J]. N Engl J Med, 1971, 285(21): 1182-1186.
[3]	O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth[J]. Cell, 1997, 88(2): 277-285.
[4]	Ramjiawan RR, Griffioen AW, Duda DG. Anti-angiogenesis for cancer revisited: is there a role for combinations with immunotherapy[J]. Angiogenesis, 2017, 20(2): 185-204.
[5]	Siwiec A, Majdan M. The role of the PD-1 protein in pathogenesis of autoimmune diseases, with particular consideration of rheumatoid arthritis and systemic lupus erythematosus[J]. Postepy Hig Med Dosw(Online), 2015, 69: 534-542. doi:10.5604/17322693.1150784.
[6]	Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1(MDX-1106)in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates[J]. J Clin Oncol, 2010, 28(19): 3167-3175.
[7]	Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis[J]. Nat Med, 2013, 19(11): 1423-1437.
[8]	Gunaje JJ, Bahrami AJ, Schwartz SM, et al. PDGF-dependent regulation of G protein signaling-5 expression and vascular smooth muscle cell functionality[J]. Am J Physiol Cell Physiol, 2011, 301(2): C478-489.
[9]	Ishikawa H, Nakao K, Matsumoto K, et al. Antiangiogenic gene therapy for hepatocellular carcinoma using angiostatin gene[J]. Hepatology, 2003, 37(3): 696-704.
[10]	Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
[11]	Zeng H, Zheng R, Guo Y, et al. Cancer survival in China, 2003-2005: a population-based study[J]. Int J Cancer, 2015, 136(8): 1921-1930.
[12]	Zheng YW, Li RM, Zhang XW, et al. Current adoptive immunotherapy in non-small cell lung cancer and potential influence of therapy outcome[J]. Cancer Invest, 2013, 31(3): 197-205.
[13]	Yao S, Zhu Y, Chen L. Advances in targeting cell surface signaling molecules for immune modulation[J]. Nat Rev Drug Discov, 2013, 12(2): 130-146.
[14]	Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer[J]. N Engl J Med, 2012, 366(26): 2443-2454.
[15]	Qian N, Gao L, Dong L, et al. Construction, expression, purification, and characterization of a dual-targeting PD-1/VEGF-A fusion protein(P-V)[J]. Protein Expr Purif, 2015, 109: 1-6. doi:10.1016/j.pep.2015.01.004.
[16]	Folkman J, Watson K, Ingber D, et al. Induction of angiogenesis during the transition from hyperplasia to neoplasia[J]. Nature, 1989, 339(6219): 58-61.
[17]	Zhao X, Su Y, You J, et al. Combining antiangiogenic therapy with neoadjuvant chemotherapy increases treatment efficacy in stage IIIA(N2)non-small cell lung cancer without increasing adverse effects[J]. Oncotarget, 2016, 7(38): 62619-62626.
[18]	Gampenrieder SP, Westphal T, Greil R. Antiangiogenic therapy in breast cancer[J]. Memo, 2017, 10(4): 194-201.
[19]	Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy[J]. Science, 2005,307(5706): 58-62.
[20]	何朗, 孙永红, 蒋莉, 等. rh-Endostatin与肿瘤血管正常化时相的关系初探[J]. 中华肿瘤防治杂志, 2016, 23(19): 1291-1296. HE Lang, SUN Yonghong, JIANG Li, et al. Preliminary research of the relationship between rh-Endostatin and micro-vascular normalization course[J]. Chin J Cancer Prevention Treatment, 2016, 23(19): 1291-1296.
[21]	Liang J, Liu X, Xie Q, et al. Endostatin enhances antitumor effect of tumor antigen-pulsed dendritic cell therapy in mouse xenograft model of lung carcinoma[J]. Chin J Cancer Res, 2016, 28(4): 452-460.
[22]	Folkman J. Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action[J]. Exp Cell Res, 2006, 312(5): 594-607.
[23]	Schmittnaegel M, Rigamonti N, Kadioglu E, et al. Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade[J]. Sci Transl Med, 2017, 12, 9(385). doi:10.1126/scitranslmed.aak9670.
[24]	Yasuda S, Sho M, Yamato I, et al. Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2(VEGFR2)induces synergistic anti-tumour effect in vivo[J]. Clin Exp Immunol, 2013, 172(3): 500-506.

Full-Text